Gene therapy for malignant glioma

Adam M. Sonabend, Ilya V. Ulasov, Karen Dana, Maciej S. Lesniak*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations


Gliomas are the most common form of primary intracranial malignancy, with glioblastoma multiforme carrying the worst prognosis. Within the context of experimental treatments for this disease, gene and viral oncolytic therapies are two promising and emerging therapeutic strategies. This review explores the different varieties of gene therapy vectors and some of the major advances in the development of oncolytic viruses for targeting these tumors from the preclinical and clinical perspectives. For both gene and oncolytic virotherapy, the limited reach of distant tumor pockets remains a major limitation of their efficacy; thus, some of the initiatives to overcome this obstacle are presented. We attempt a critical review of the available literature with a focus on the present challenges in the field of glioma gene therapy.

Original languageEnglish (US)
Title of host publicationTherapeutic Ribonucleic Acids in Brain Tumors
PublisherSpringer-Verlag Berlin Heidelberg
Number of pages22
ISBN (Electronic)9783642004759
ISBN (Print)9783642004742
StatePublished - Jan 1 2009

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Gene therapy for malignant glioma'. Together they form a unique fingerprint.

Cite this